SCHEMBL2194237

SCHEMBL2194237

c1ccc(-c2ccc3c(NCc4cccnc4)noc3c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 9/20 0.53
CYP3A4 P08684 9/20 0.53
CYP2C19 P33261 9/20 0.53
CYP2C9 P11712 5/20 0.53
CYP2D6 P10635 8/20 0.51
ALDH1A1 P00352 6/20 0.51
HSD17B10 Q99714 6/20 0.51
CLK4 Q9HAZ1 6/20 0.51
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
PDE5A O76074 2/20 0.51
POLB P06746 2/20 0.51
KDM4E B2RXH2 2/20 0.51
HPGD P15428 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
MAPK1 P28482 3/20 0.50
TSHR P16473 3/20 0.50
USP2 O75604 2/20 0.50
HIF1A Q16665 2/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2198146 0.91 CLK4 (0.50) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL2196171 0.86 EPHX2 (0.50) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL2197166 0.85 EGFR (0.53) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL2197577 0.85 CYP3A4 (0.62) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL13146631 0.83 POLB (0.55) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL2198123 0.81 HPGD (0.54) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL2198240 0.81 ALDH1A1 (0.54) ALDH1A1KMT2APDE5APOLBKDM4E
SCHEMBL2198386 0.81 PDE5A (0.53) ALDH1A1CLK4KMT2APDE5AHPGD
SCHEMBL2197915 0.81 CLK4 (0.52) CYP1A2CYP3A4CYP2C19CYP2C9CYP2D6
SCHEMBL2197333 0.80 PDE5A (0.48) ALDH1A1CLK4KMT2AMEN1PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977360-B2 Benzo[d]isoxazol-3-yl-amine compounds and their use as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2011-07-12 US claimed
EP-1888541-B1 BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20090042945-A1 Benzo[d]isoxazol-3-yl-amine Compounds and Their Use as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2009-02-12 US claimed
EP-1888541-A1 BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2008-02-20 EP claimed
WO-2006122799-A1 BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2006-11-23 WO claimed
US-7977360-B2 Benzo[d]isoxazol-3-yl-amine compounds and their use as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2011-07-12 US disclosed
EP-1888541-B1 BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20090042945-A1 Benzo[d]isoxazol-3-yl-amine Compounds and Their Use as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2009-02-12 US disclosed
EP-1888541-A1 BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2008-02-20 EP disclosed
WO-2006122799-A1 BENZO(D)ISOXAZOL-3-YL-AMINE COMPOUNDS AND THEIR USE AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042945-A1 Benzo[d]isoxazol-3-yl-amine Compounds and Their Use as Vanilloid Receptor Ligands TRPV1, TRPV3, TRPV5 CYP1A2 1200/4885CYP3A4 716/4885CYP2C19 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.